Tau inhibition
Preventing and dissolving tau tangles in the brain to disrupt neurodegenerative cascades
Undoing the tangles
We have developed a potential treatment for Alzheimer’s disease by targeting the tau pathological process. Our product, Hydromethylthionine Mesylate (HMTM), belongs to a class of drugs known as Tau Aggregation Inhibitors (TAIs).
TAIs prevent and dissolve tau aggregates in the brain, preserving the normal tau function essential for a healthy brain. By undoing the tangles that cause dementia, we aim to slow and potentially stop memory loss and other symptoms associated with Alzheimer’s disease.
Potential for several
applications
We have “composition of matter” patents and “use” patents covering the application of our TAIs for the treatment and prevention of Alzheimer’s and frontotemporal dementia (FTD). We are also exploring the use of TAIs in several other neurodegenerative diseases associated with tau pathology, as well as other disorders deriving from the aggregation of other proteins in the brain, including Parkinson’s disease and Huntington’s disease.
